

## DAFTAR PUSTAKA

1. Pengurus Besar Perkumpulan Endokrinologi Indonesia (PERKENI). Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia Tahun 2021. *Pb Perkeni* **6**, (2021).
2. Federation, I. D. Diabetes Facts & Figures. at (2025).
3. Bae, J., Yu, M. H., Lee, M., Cha, B. S. & Lee, B. W. Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. *Endocrinol. Metab.* **40**, 258–267 (2025)
4. Federation, I. D. Indonesia — IDF Western Pacific Members. at (2025).
5. Widyastuti, Wa Ode Sri Asnaniar & Ernasari. Tingkat Pengetahuan Pasien Diabetes Melitus pada Pencegahan Luka Kaki Diabetes. *Wind. Nurs. J.* **4**, 1–8 (2023).
6. Riskesdas. *Laporan Provinsi Sulawesi Selatan Riskesdas 2018. Badan Penelitian Dan Pengembangan Kesehatan* vol. 110 (2018).
7. Ackroyd, S. Understanding type 2 diabetes. *Nursing standard (Royal College of Nursing (Great Britain): 1987)* vol. 14 55 at <https://doi.org/10.7748/ns2000.05.14.33.55.c2833> (2000).
8. Sarihati, I. G. A. D., Karimah, H. N. & Habibah, N. GAMBARAN KADAR HbA1C PADA PASIEN DIABETES MELITUS TIPE 2 DI RSUD WANGAYA. *Meditory J. Med. Lab.* **6**, 88–98 (2019).
9. Wang, M. & Hng, T. HbA1c: More than just a number. *Aust. J. Gen. Pract.* **50**, 628–632 (2021).
10. Suastika, K. Clinical Use and Limitation of Hemoglobin A1c Examination. *Clin. Diabetol.* (2021) doi:10.5603/DK.A2021.0045.
11. Ono, R. *et al.* Comparison of the efficacy of anti-diabetic medications as add-on to metformin in type 2 diabetes mellitus from a real-world database. *BMC Pharmacol. Toxicol.* **24**, 1–11 (2023).
12. Ulhaq, D. D., Indrawijaya, Y. Y. A. & Suryadinata, A. Analisis Efektivitas Biaya Terapi Kombinasi Insulin dengan Obat Antidiabetes Oral pada Pasien Rawat Jalan Penderita Diabetes Melitus Tipe 2 di RSUD dr. Soehadi Prijonegoro Sragen. *J. Islam. Pharm.* **7**, 112–118 (2023).
13. Pengurus Besar Perkumpulan Endokrinologi Indonesia (PERKENI). *Pedoman Pengelolaan Dan Pencegahan Diabetes Melitus Tipe 2 Dewasa Di Indonesia 2024.* (Pengurus Besar Perkumpulan Endokrinologi Indonesia (PB PERKENI), 2024).
14. Akuba, J., Wiedyaningsih, C. & Andayani, T. M. Pengaruh Medication Therapy Management terhadap Kadar HbA1c Pasien Diabetes Melitus yang Mendapatkan Terapi Insulin. *Maj. Farm.* **21**, 37–44 (2024).
15. Widiyastuti, K. R., Made, I., Wijaya, K. & Suputra, P. A. Tatalaksana Diabetes Melitus Tipe II. *Ganesha Med. J.* **1**, 114–120 (2021).
16. Mellitus, D. [ Thesis – Drug Innovation Master Program ] Research Question :

- (2011).
17. Kurnia, J., Mulyadi, N. & Rottie, J. Hubungan Kualitas Tidur Dengan Kadar Glukosa Darah Puasa Pada Pasien Diabetes Melitus Tipe 2 Di Rumah Sakit Pancaran Kasih Gmim Manado. *J. Keperawatan UNSRAT* **5**, 106524 (2017).
  18. Hakyan, V. PERSPECTIVE Diabetes Management Polyphagia's impact on health and quality of life: Management of excessive hunger and its implications. *Perspective* **13**, 508–509 (2023).
  19. Hu, C. Commentary Reasons For Unexplainable Weight Loss Among Diabetics. *African J. Diabetes Med.* **30**, 2022 (2022).
  20. Kumar, P. R. *et al.* Utility of Glycated Hemoglobin in Diagnosing Type 2 Diabetes Mellitus: A Community-Based Study. *J. Clin. Endocrinol. Metab.* **95**, 2832–2835 (2010).
  21. Little, R. R., Rohlfing, C. & Sacks, D. B. The National Glycohemoglobin Standardization Program: Over 20 Years of Improving Hemoglobin A1c Measurement. *Clin. Chem.* **65**, 839–848 (2019).
  22. Młynarska, E. *et al.* Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. *Int. J. Mol. Sci.* **26**, (2025).
  23. Khalid-Al-Azam, M., Sarkar, S. K. & Hasan, S. M. M. Adherence to lifestyle interventions and its effect on metabolic and behavioral outcomes in type 2 diabetes mellitus cases. *Int. J. Community Med. Public Heal.* **12**, 1611–1616 (2025).
  24. Linden, S. & Erwina, W. Terapi Penggunaan Obat Antidiabetik Oral Pada Pasien Diabetes Melitus Tipe 2 Rawat Jalan Di Rumah Sakit Swasta, Samarinda. *J. Pharm. Sci.* **5**, 2014–226 (2022).
  25. Care, D. & Suppl, S. S. 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2025. *Diabetes Care* **48**, S181–S206 (2025).
  26. Horváth, L., Novodvorský, P. & Haluzik, M. Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist. *Diabetes, Obes. Metab.* **27**, 42–54 (2025).
  27. Rhee, S. Y. *et al.* Monotherapy in Patients with Type 2 Diabetes Mellitus. *Diabetes Metab. J.* **41**, 349–356 (2017).
  28. Qian, D. *et al.* Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. *Diabetes Ther. Res. Treat. Educ. diabetes Relat. Disord.* **9**, 1945–1958 (2018).
  29. Moon, M. K. *et al.* Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus. *Korean J. Intern. Med.* **32**, 974–983 (2017).
  30. Dutta, S. *et al.* Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes. *Drug Des. Devel. Ther.* **17**, 1907–1932 (2023).
  31. Foretz, M., Guigas, B. & Viollet, B. Metformin: update on mechanisms of action and repurposing potential. *Nat. Rev. Endocrinol.* **19**, 460–476 (2023).

32. Hur, K. Y. *et al.* Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. *Diabetes Metab J* **44**, 3–10 (2020).
33. Lebovitz HE. Therapy for Diabetes Mellitus and Related Disorders. in *Therapy for Diabetes Mellitus and Related Disorders* (ed. Lebovitz HE) 164–175 (American Diabetes Association, 2014). doi:10.2337/9781580405096.
34. Young, L. H. *et al.* Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. *Circulation* **135**, 1882–1893 (2017).
35. Davies, M. J. *et al.* Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* **45**, 2753–2786 (2022).
36. Genua, I. & Cusi, K. Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies. *Diabetes Spectr.* **37**, 48–58 (2024).
37. Zhu, Z.-N., Jiang, Y.-F. & Ding, T. Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials. *Bone* **68**, 115–123 (2014).
38. Uuh Narvaez, J. J. & Segura Campos, M. R. Combination therapy of bioactive compounds with acarbose: A proposal to control hyperglycemia in type 2 diabetes. *J. Food Biochem.* **46**, e14268 (2022).
39. Akmal, M., Patel, P. & Wadhwa, R. Alpha Glucosidase Inhibitors. in (Treasure Island (FL), 2025).
40. Omar, B. & Ahrén, B. Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors. *Diabetes* **63**, 2196–2202 (2014).
41. M., S. B. *et al.* Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. *N. Engl. J. Med.* **369**, 1317–1326 (2025).
42. Zannad, F. *et al.* Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. *Lancet* **385**, 2067–2076 (2015).
43. J.L., H. H. *et al.* Dapagliflozin in Patients with Chronic Kidney Disease. *N. Engl. J. Med.* **383**, 1436–1446 (2020).
44. Kim, N. H. & Kim, N. H. Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics. *Diabetes Metab J* **46**, 543–551 (2022).
45. J.V., M. J. *et al.* Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N. Engl. J. Med.* **381**, 1995–2008 (2019).
46. McGuire, D. K. *et al.* Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA Cardiol.* **6**, 148–158 (2021).
47. Bernard, Z. *et al.* Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N. Engl. J. Med.* **373**, 2117–2128 (2025).
48. Rodbard, H. W. *et al.* Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. *Diabetes Care* **42**,

- 2272–2281 (2019).
49. Aroda, V. R. *et al.* PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. *Diabetes Care* **42**, 1724–1732 (2019).
  50. Pratley, R. *et al.* Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet* **394**, 39–50 (2019).
  51. Mosenson, O. *et al.* Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes Endocrinol.* **7**, 515–527 (2019).
  52. Sanda, E. Y., Yunus, M., Novriani, E., Kedokteran, F. & Gigi, K. Perbandingan Efektivitas Penggunaan Obat Oral Antiabetik Tunggal dan Kombinasi pada Pasien Diabetes Mellitus Tipe 2 di Rumah Sakit Umum Royal Prima Medan. **5**, (2025).